RESTASIS

Peak

cyclosporine

NDAOPHTHALMICEMULSIONPriority Review
Approved
Dec 2002
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Calcineurin Inhibitors

Pharmacologic Class:

Calcineurin Inhibitor Immunosuppressant

Clinical Trials (5)

NCT06837259Phase 1Completed

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults

Started Mar 2025
26 enrolled
Healthy Adults
NCT05946772Phase 2Recruiting

Cyclosporine In Takotsubo Syndrome

Started Feb 2025
204 enrolled
Takotsubo Cardiomyopathy
NCT06541678Phase 1Completed

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Started Dec 2024
16 enrolled
Healthy
NCT05745701Phase 1Completed

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Started Feb 2023
16 enrolled
Healthy
NCT05573230Phase 1Completed

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Started Oct 2022
32 enrolled
Healthy

Loss of Exclusivity

LOE Date
May 11, 2034
99 months away
Patent Expiry
May 11, 2034

Patent Records (4)

Patent #ExpiryTypeUse Code
8292129
Feb 25, 2031
Product
8561859
Apr 16, 2032
Product
9676525
Feb 7, 2034
Product
9669974
May 11, 2034
Product